Melchizedek Penacerrada
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 5
- SARS-CoV-2 and COVID-19 Research 2
- Genetics 7
- Genetic Associations and Epidemiology 7
- Journals
- The Lancet (4 papers)Nature (4 papers)Human Genetics (1 paper)Trials (1 paper)Human Genetics and Genomics Advances (1 paper)
- Partner nations
- United KingdomSwedenVietnam
In The Last Decade
Melchizedek Penacerrada
11 papers receiving 2.1k citations
Melchizedek Penacerrada's Hit Papers
Peers
Comparison fields: 5 of 96
- Infectious Diseases 1.3k
- Genetics 521
- Applied Microbiology and Biotechnology 34
- Internal Medicine 28
- Immunology 111
Countries citing papers authored by Melchizedek Penacerrada
This map shows the geographic impact of Melchizedek Penacerrada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melchizedek Penacerrada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melchizedek Penacerrada more than expected).
Fields of papers citing papers by Melchizedek Penacerrada
This network shows the impact of papers produced by Melchizedek Penacerrada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melchizedek Penacerrada. The network helps show where Melchizedek Penacerrada may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 5 | 2021 | 213 | |
| 6 | Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial Hit paper breakdown → | 2020 | 181 |
| 7 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 8 | 2023 | 60 | |
| 9 | 2021 | 26 | |
| 10 | 2024 | 8 | |
| 11 | 2024 | 5 | |
| 12 | 2021 | 0 |
About Melchizedek Penacerrada
Melchizedek Penacerrada is a scholar working on Infectious Diseases, Genetics, Hepatology, Surgery and Nuclear Energy and Engineering, having authored 12 papers that have together received 2.2k indexed citations. Recurring topics across this work include Genetic Associations and Epidemiology (7 papers), COVID-19 Clinical Research Studies (5 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Esophageal Cancer Research and Treatment (1 paper) and Liver Disease and Transplantation (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Genetics (521 citations), Applied Microbiology and Biotechnology (34 citations), Internal Medicine (28 citations) and Immunology (111 citations). Melchizedek Penacerrada has collaborated with scholars based in United Kingdom, Sweden and Vietnam. Their work appears in journals such as The Lancet, Nature, Human Genetics, Trials and Human Genetics and Genomics Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.